RE:A good laugh before the weekend I’m at a bit of a loss on this one.
So, peak sales of Trogarzo are $250 million.
Let’s say Egrifta shows normal growth (unreasonable assumption but work with me) then it would be $50 million at least.
So, $300 million in peak sales.
Market cap at $10 is maybe $800 million fully diluted (prob less).
Let’s forget the cash as they’ll have to pay off the deal if SP is still low.
So, Market cap is 2.66x peak sales?!?
Some pharma companies go for 8 times peak sales.
I think TH should be valued at 5 times peak sales at least.....market cap of $1.5 Billion or target price of $20 in a couple years.
That is a conservative target.
$10 does not make sense to me....
SPCEO....it may be time to make another spreadsheet to show the impact of increased Egrifta scripts on revenue and the bottom line.
If Luc is willing to add 2 MSL’s, I suspect with F4 and the new marketing campaign that we will see a 25%+ increase in Egrifta scripts by the end of the year.
bfw
juniper88 wrote: Especially line about "baked in..." I almost fell of my chair
| Analyst Actions: RBC Capital Maintains Sector Perform, $10 TP on Theratechnologies |
|
02:03 PM EDT, 04/05/2019 (MT Newswires) -- RBC Capital has reiterated its Sector Perform rating and $10 TP on Theratechnologies. The Trogarzo launch continues to exhibit steady growth, and RBC says it sees peak out-year sales of ~$250 million. The brokerage added that Egrifta sales were also stable q-o-q, with recent NAFLD data potentially augmenting TH's relaunch strategy that could bolster life cycle and revenue in the medium-term. "Overall, we continue to believe Trogarzo and Egrifta should continue to grow, but with peak opportunities mostly baked into shares at current levels." (TH reported Trogarzo revenues of $6.1 million, slightly above RBC's $5.4 million est. Egrifta sales of $9.0 million were essentially flat q-o-q and below RBC's $10.1 million estimate.) |